Can a Blood-Clot drug tame severe COVID-19?

NCT ID NCT04652115

Recruiting now Disease control Sponsor: Brigham and Women's Hospital Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 21, 2026 · Updated 3 times

Summary

This study tests whether a drug called defibrotide is safe and feasible for people with severe COVID-19 pneumonia. About 42 adults with confirmed COVID-19 and lung infiltrates will receive the drug intravenously. Researchers will monitor for bleeding and low blood pressure as key safety concerns.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Defibrotide (given intravenously)
What this could lead to: If it works, this could point toward a new treatment to reduce complications in severe COVID-19 pneumonia.
What could go wrong: This is a small, early-phase safety study with only 42 participants, so it may not prove effectiveness. There are also risks of bleeding and low blood pressure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID19 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

COVID-19

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID19

Contacts and locations

Locations

Brigham and Women's Hospital
RECRUITING

Boston, Massachusetts, 02214, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.